AstraZeneca: shares confirm rebound after FDA decision.
(CercleFinance.com) - AstraZeneca said on Monday that it has received breakthrough therapy designation from the US Food and Drug Administration for a lung cancer drug, resulting in its shares rising slightly in London.
AstraZeneca and its research and development unit MedImmune today announced that the FDA has granted breakthrough therapy designation for Imfinzi (durvalumab) for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.
The FDA's decision follows a recent accelerated US approval for Imfinzi in previously-treated patients with advanced bladder cancer.
The news also comes less than a week after after the firm said that a combination of Imfinzi and tremelimumab did not improve progression-free survival compared to chemotherapy in non-small cell lung cancer patients in a Phase III trial, which prompted the shares to tumble over 15 percent last Thursday.
AstraZeneca shares are currently up 1.7% at 4,559 pence this morning after losing over 12 percent last week.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
AstraZeneca and its research and development unit MedImmune today announced that the FDA has granted breakthrough therapy designation for Imfinzi (durvalumab) for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.
The FDA's decision follows a recent accelerated US approval for Imfinzi in previously-treated patients with advanced bladder cancer.
The news also comes less than a week after after the firm said that a combination of Imfinzi and tremelimumab did not improve progression-free survival compared to chemotherapy in non-small cell lung cancer patients in a Phase III trial, which prompted the shares to tumble over 15 percent last Thursday.
AstraZeneca shares are currently up 1.7% at 4,559 pence this morning after losing over 12 percent last week.
Copyright (c) 2017 CercleFinance.com. All rights reserved.